Cholinesterase Inhibitors Market Size

Cholinesterase Inhibitors Market size is expected to cross USD 180 Billion by the end of 2036, growing at a CAGR of 9% during the forecast period, i.e., 2024-2036. In the year 2023, the industry of cholinesterase inhibitors was USD 20 Billion. The market growth is wheeled majorly by the growing prevalence of and hike in frequency rate of dementia caused because of Alzheimer’s and Parkinson’s diseases all over the world. Recently, more than 55 million people have been suffering from dementia globally, over 60% of whom live in low- and middle-income countries, and women are more disproportionately influenced by dementia. Every year, there are nearly 10 million new cases.

The second major factor that is anticipated to drive the growth of the cholinesterase inhibitors market in the forecast period is the prevalence of LATE disease in elderly people and the increase in the percentage of aged people across the planet. Depending on the newest estimations, the number of people older than 65 years with Alzheimer’s dementia is projected to reach 12.7 million by 2050. For instance, a group of researchers assessed the brains of 6,196 people with an average age at death of 88 years and discovered that almost 40% of them may have got limbic-predominant age-related TDP-43 encephalopathy (LATE). LATE creates symptoms equivalent to Alzheimer’s, comprising issues with thinking, reminding, and reasoning, but has other inherent causes involving abnormal clusters of a protein called TDP-43. This protein is also included in frontotemporal dementia, but LATE shows a distinctive pattern of brain transformations and tends to impact people over the age of 80. Therefore, this might increase and drive the market expansion of cholinesterase inhibitors as this is the only effective therapy to cure these diseases.